SCHEMBL1190488

SCHEMBL1190488

O=C(c1ccc(O)c(Br)c1)N1CCOc2ccncc21

nearest known ligand 0.79

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 8/20 0.79
SLC22A6 Q4U2R8 1/20 0.79
SLC22A8 Q8TCC7 1/20 0.79
KCNH2 Q12809 1/20 0.45
POLB P06746 1/20 0.44
NR3C2 P08235 1/20 0.42
GPBAR1 Q8TDU6 1/20 0.41
CTSD P07339 1/20 0.38
SCD5 Q86SK9 1/20 0.37
CYP11B2 P19099 1/20 0.36
KMT2A Q03164 1/20 0.36
NOTUM Q6P988 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
FAAH O00519 1/20 0.35
NAAA Q02083 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1190077 0.99 SLC22A12 (0.77) SLC22A12SLC22A6SLC22A8KCNH2POLB
SCHEMBL1190582 0.95 SLC22A12 (0.71) SLC22A12SLC22A6SLC22A8KCNH2POLB
SCHEMBL1191178 0.91 SLC22A12 (0.65) SLC22A12SLC22A6SLC22A8KCNH2POLB
Bromide SCHEMBL1190958 0.90 SLC22A12 (0.64) SLC22A12SLC22A6SLC22A8KCNH2POLB
Epaminurad SCHEMBL1191165 0.88 SLC22A12 (1.00) SLC22A12SLC22A6SLC22A8KCNH2POLB
SCHEMBL13036626 0.87 SLC22A12 (0.67) SLC22A12SLC22A6SLC22A8KCNH2POLB
SCHEMBL1190085 0.87 SLC22A12 (0.67) SLC22A12SLC22A6SLC22A8KCNH2POLB
SCHEMBL1191676 0.87 SLC22A12 (0.67) SLC22A12SLC22A6SLC22A8KCNH2POLB
Epaminurad SCHEMBL1191581 0.87 SLC22A12 (0.98) SLC22A12SLC22A6SLC22A8KCNH2POLB
Epaminurad SCHEMBL1190282 0.87 SLC22A12 (0.98) SLC22A12SLC22A6SLC22A8KCNH2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266989-B1 HETEROCYCLIC DERIVATIVES C & C RES LAB (KR) 2015-09-02 EP claimed
US-8394792-B2 Heterocyclic derivatives C&C RESEARCH LABORATORIES (KR) 2013-03-12 US claimed
CN-102015726-A Heterocyclic derivatives C & C RES LAB 2011-04-13 CN claimed
US-20110028467-A1 HETEROCYCLIC DERIVATIVES C&C RESEARCH LABORATORIES (KR) 2011-02-03 US claimed
EP-2266989-A2 HETEROCYCLIC DERIVATIVES C&c Research Laboratories (KR) 2010-12-29 EP claimed
EP-2266989-B1 HETEROCYCLIC DERIVATIVES C & C RES LAB (KR) 2015-09-02 EP disclosed
US-8394792-B2 Heterocyclic derivatives C&C RESEARCH LABORATORIES (KR) 2013-03-12 US disclosed
US-8394792-B2 Heterocyclic derivatives C&C RESEARCH LABORATORIES (KR) 2013-03-12 US disclosed
US-8394792-B2 Heterocyclic derivatives C&C RESEARCH LABORATORIES (KR) 2013-03-12 US disclosed
CN-102015726-A Heterocyclic derivatives C & C RES LAB 2011-04-13 CN disclosed
US-20110028467-A1 HETEROCYCLIC DERIVATIVES C&C RESEARCH LABORATORIES (KR) 2011-02-03 US disclosed
US-20110028467-A1 HETEROCYCLIC DERIVATIVES C&C RESEARCH LABORATORIES (KR) 2011-02-03 US disclosed
US-20110028467-A1 HETEROCYCLIC DERIVATIVES C&C RESEARCH LABORATORIES (KR) 2011-02-03 US disclosed
EP-2266989-A2 HETEROCYCLIC DERIVATIVES C&c Research Laboratories (KR) 2010-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028467-A1 HETEROCYCLIC DERIVATIVES XDH, NUDT1, UGDH SLC22A12 692/4885SLC22A6 625/4885SLC22A8 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.